CAJ | 학술논문

革兰阳性菌是ICU最为重要的致病菌之一，万古霉素作为一线用药对其感染疗效肯定。近期指南推荐的万古霉素血药浓度在临床应用较为广泛，但临床医师对增高的谷浓度所面临的不良反应（主要为肾功能损害）仍十分关注。现就万古霉素及其在急、危重症患者等特殊群体中药代/药效动力学，治疗方案的调整和相关肾损伤等方面予以综述。
혁란양성균시ICU최위중요적치병균지일，만고매소작위일선용약대기감염료효긍정。근기지남추천적만고매소혈약농도재림상응용교위엄범，단림상의사대증고적곡농도소면림적불량반응（주요위신공능손해）잉십분관주。현취만고매소급기재급、위중증환자등특수군체중약대/약효동역학，치료방안적조정화상관신손상등방면여이종술。
Gram-positive bacteria is one of the most important pathogens in ICU. The effect that vancomycin against the infection is certainly. Recent guidelines recommend serum concentrations of vancomycin is widely used in clinical, but adverse reactions together with higher trough concentration (primarily kidney damage) is still very concerned. Now we reviewed vancomycin and its pharmacokinetics in critically ill patients, adjustment of treatment programs and associated kidney injury.